Fluticasone versus 'extrafine' HFA-beclomethasone dipropionate for chronic asthma in adults and children

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2006, Pages

  Lasserson, Toby J ^a   Cates, Christopher J ^b   Lasserson, Emma H ^c   White, John ^d  

^a The Cochrane Collaboration   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c Stonecot Surgery   (United Kingdom)

^d YORK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85102984567     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005309.pub3     Document Type: Review

References (73)

1. Ahrens RC, Hendeles L, Teresi M, Lux CR, van den Burgt J, Hart KA, et al. Relative potency of beclomethasone propionate (BDP), delivered by HFA-MDI, and fluticasone propionate (FP) delivered by diskus [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract No: P1576.
2. Aubier M, Wettenger R, Gans SJ. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma. Respiratory Medicine 2001;95(3):212-20.
3. O'Reilly JF, Stephenson PS, Evans KE. Cost-effectiveness of fluticasone compared with beclomethasone extrafine aerosol. European Respiratory Journal 2001;18(Suppl 33):49S.
4. Wettengel R, Aubier M, Gans SJ. Equivalence study of 800 mcg/day HFA-BDP extrafine aerosol and 1000 mcg/day HFA-fluticasone propionate. American Journal of Respiratory and Critical Care Medicine 2000;161(Suppl 3):A186.
5. Currie GP, Fowler S, Wilson A, Sims EJ, Orr L, Lipworth BJ. Airway systemic ratio of hydrofluoroalkane fluticasone and beclomethasone in asthmatics [Abstract]. Journal of Allergy, Asthma and Immunolgy 2002;109(Suppl 1):Abstract No: 769.
6. Currie GP, Fowler SJ, Wilson AM, Sims EJ, Orr LC, Lipworth BJ. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax 2002;57(10):865-8.
7. Fairfax A, Hall I, Spelman R. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. Annals of Allergy, Asthma and Immunology 2001;86(5):575-82.
8. Giraud V, Martinat Y, Molimard M. Improvement of asthma control: comparative study with beclomethasone extra fine aerosol, fluticasone or budesonide [Abstract]. American Thoracic Society 100th International Conference, May 21-26. 2004:A37, Poster J121.
9. Molimard M, Martinat Y, Rogeaux Y, Moyse D, Pello JY, Giraud V. Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Respiratory Medicine 2005;99(6):770-8.
10. Robroeks C, van de Kant K, Dompeling E, van Vilet D, Kester A, Hendriks H, et al. [Abstract]. Comparison of the anti inflammatory effects of extra fine HFA beclomethasone (BDP) versus fluticasone (FP)-DPI on inflammatory markers in exhaled breath in childhood asthma. European Respiratory Journal. 2007; Vol. 30 (Suppl 51):385s.
11. Robroeks CMHHT, Van De Kant KDG, Van Vliet D, Kester AD, Hendriks HJE, Damoiseaux JGMC, et al. Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone versus fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma. Annals of Allergy, Asthma and Immunology 2008;100(6):601-7.
12. Thongngarm T, Silkoff PE, Kossack WS, Nelson HS. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. Journal of Asthma 2005;42(4):257-63.
13. Tunon-de-Lara JM, Laurent F, Giraud V, Perez T, Aguilaniu B, Meziane H. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. Journal of Allergy & Clinical Immunology 2007;119(3):583-90.
14. Price D, Van Aalderen WM, De Baets FM, Price J. A double-blind comparison of fluticasone (FP) and beclomethasone extra-fine aerosol (HFA-BDP) in children with symptomatic mild to moderate asthma. Allergy. 2003; Vol. 58, issue Suppl 74:177.
15. Price J, Van Aalderen WM, De Baets FM, Price D. Dose comparability of fluticasone (F) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma using dose step down study design [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract no. 3344.
16. Van Aalderen WMC, Hugen CAC. Asthma quality of life and systemic safety of beclomethasone extrafine aerosol (Q) and fluticasone in children. World Allergy Organisation Congress, Vancouver, Canada, 7-12 September. 2003; Vol. Suppl 1:P-2-37.
17. van Aalderen WM, Price D, De Baets FM, Price J. Beclometasone dipropionate extrafine aerosol versus fluticasone propionate in children with asthma. Respiratory Medicine 2007;101(7):1585-93.
18. Dubus JC, Mely L, Huiart L, Marguet C, Le Roux P. Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma. Fundamental & Clinical Pharmacology 2003;17(5):627-31.
19. Ederle K, Hadar S, Vortkamp M. Asthma symptom control improves following switch from conventional inhaled steroid to hydrofluoroalkane beclomethasone dipropionate extrafine aerosol (HFA-BDP). American Journal of Respiratory and Critical Care Medicine 2002;165(Suppl 8):A769.
20. Multicentre Study Group. Improved control of asthma symptoms with a reduced dose of HFA-BDP extrafine aerosol: an open-label, randomised study. European Review for Medical & Pharmacological Sciences 2003;7(2):45-55.
21. Adams JE, Egan J, et al. Effects on bone mineral density of inhaled corticosteroids (fluticasone propionate and beclomethasone dipropionate: a two year double-blind randomised study [Abstract]. Osteoporosis International 1996;6(Suppl 1):287.
22. Egan J, Kalra S, Adams JE, Eastell R, Maden C, Woodcock A. A two-year double-blind randomised study comparing the effects of fluticasone propionate 1000 mcg/day and beclomethasone dipropionate 2000 mcg/day on bone mineral density and bone metabolism in asthma patients. European Respiratory Journal 1996;9(Suppl 23):52s.
23. Egan JJ, Maden C, Kalra S, Adams JE, Eastell R, Woodcock AA. A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. European Respiratory Journal 1999;13(6):1267-75.
24. Frezza G, Terra-Filho J, Martinez JA, Vianna EO. Rapid effect of inhaled steroids on nocturnal worsening of asthma. Thorax 2003;58(7):632-3.
25. Geppe NA, Karpushkina AV, Kolossova NG, Yarovaya EB. The effects of fluticasone propionate/salmeterol 50/100ug bid in children with asthma versus beclometasone propionate 200ug BD fluticasone propionate 100ug bid dry powder inhalers [Abstract]. European Respiratory Journal 2004;24(Suppl 48):378s.
26. Gregson RK, Rao R, Murrills A J, Taylor PA, Warner JO. Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Osteoporosis International 1998;8(5):418-22.
27. Horiguchi T, Hayashi N, Ohira D, Torigoe H, Ito T, Hirose M, et al. Usefulness of HFA-BDP for adult patients with bronchial asthma: randomized crossover study with fluticasone. Journal of Asthma 2006;43(7):509-12.
28. Huchon G, Mueser M, Lefrancois G. Acceptability and efficacy of beclomethasone dipropionate (Béclojet HFA®) and fluticasone dipropionate (Flixotide HFA®, FDP) associated with the Volumatic® spacer in adults with mild to moderate persistent asthma. European Respiratory Journal 2003;22(Suppl 45):Abstract No: P2989.
29. Khalilzadeh S, Boloorsaz MR, Safavi A, Velayati AA. Efficacy and safety of inhaled steroids in children with asthma: A comparison of fluticasone propionate with beclomethasone. Tanaffos 2007;6(1):29-35.
30. Kesten S. Inhaled steroids in the long-term treatment of asthma: a double-blind, randomised, parallel group comparison of fluticasone propionate 500 µg daily and beclomethasone dipropionate 1000 µg daily over 12 months [Abstract]. European Respiratory Journal 1993;6(Suppl 17):257s.
31. Lundback B, Alexander M, Day J, Hebert J, Holzer R, Van Uffelen R, et al. Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler. Respiratory Medicine 1993;87:609-20.
32. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. American Journal of Respiratory & Critical Care Medicine 2002;165(10):1377-83.
33. Medici TC, Grebski E, Häcki M, Rüegsegger P, Maden C, Efthimiou J. Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomised parallel group study in adult asthmatic subjects. Thorax 2000;55:375-82.
34. Medici TG, Grebski E, Hacki M, Ruegsegger P, Maden C, Efthimiou J. One-year treatment with inhaled fluticasone propionate or beclomethasone dipropionate does not affect bone density and bone metabolism. A randomised, parallel group study in adult asthmatics. American Journal of Respiratory & Critical Care Medicine 1998;157:A407.
35. Migliori GB, Della Bianca A, Aliani M, Spada E, Meriggi A, Bacchella L, et al. Effect of long term inhaled fluticasone propionate (FP) 250mcg bd and beclomethasone dipropionate (BDP) 500 BCG BD of marker of bone turn over in asthmatic adult patients. European Respiratory Society; Oct 9-13; Madrid, Spain. 1999:P3110.
36. Mortimer KJ, Harrison TW, Tang Y, Wu K, Lewis S, Sahasranaman S, et al. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. British Journal of Clinical Pharmacology 2006;62(4):412-9.
37. Murray JJ, Friedman B, Chervinsky P, Fogarty C, Baker JW, Rogenes PR, et al. Fluticasone propionate (FP) is more effective than higher doses of beclomethasone dipropionate (BDP) in patients with moderate asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine 1998;157(Suppl 3):A407.
38. Ohbayashi H, Adachi M, Ichinose M, Ohta K, Kokubu F, Sano Y, et al. A multicenter, open-label, randomized comparison of suppressive effects on asthmatic inflammation of lower airways and improved effects on health-related QOL between HFA-BDP and fluticasone propionate. Japanese Journal of Allergology 2007;56(6):577-86.
39. Ohbayashi H, Adachi M, Ichinose M, Ohta K, Kokubu F, Tamura G, et al. A multicenter open label randomized comparison of the effects of HFA-BDP and FP on asthmatic inflammation of lower airways and health related quality of life. European Respiratory Journal. 2007; Vol. 30 (Suppl 51):616s.
40. Ohbayashi H, Adachi M. HFA-BDP effectively improves airway eosinophilic inflammation including the distal airways of patients with moderately severe asthma as compared with FP in a randomized open cross study [Abstract]. American Thoracic Society International Conference, May 16-21. 2008:A616.
41. Ohbayashi H, Adachi M. Hydrofluoroalkane-beclomethasone dipropionate effectively improves airway eosinophilic inflammation including the distal airways of patients with mild to moderate persistent Asthma as compared with fluticasone propionate in a randomized open double-cross study. Allergology International 2008;57(3):231-9.
42. Parakh U, Gupta K, Sharma S, Gaur SN. A comparative evaluation of the efficacy of inhaled beclomethasone dipropionate budesonide and fluticasone propionate in the management of bronchial asthma. Indian Journal of Allergy Asthma and Immunology 2004;18(1):33-8.
43. Prasad R, Bandhu M, Kant S, Pandey US, Ahuja RC, Agarwal CG. A comparative study on efficacy of inhaled fluticasone propionate and beclomethasone dipropionate in patients of bronchial asthma. Indian Journal of Allergy, Asthma & Immunology 2004;18(2):73-7.
44. Price DB, Moseley C. Cost of changing treatment with CFC-BDP ro HFA-BDP extrafine aerosol 'QVAR' in a "Real Life" clinical trial design over 1 year. American Journal of Respiratory and Critical Care Medicine 2000;161(Suppl 3):A185.
45. Price DB, Pearson M, Cresenzi K. Asthma patient treatment goals and lung function - fluticasone propionate and beclomethasone dipropionate compared in a "real-life" trial design. European Respiratory Society; Oct 9-13; Madrid, Spain. 1999:P3113.
46. Tatsis G, Kotsifas K, Filaditaki V, Makrantoni G, Boulia S. Efficacy of beclomethasone dipropionate HFA 200 microg once daily in chronic obstructive pulmonary disease and bronchial asthma. Journal of International Medical Research 2007;35(3):361-73.
47. Thomas S, Parthasarathi G, Palaksha S, Jayaraj BS, Gowda HB, Mahesh PA. Quality of life assessment in asthmatic patients receiving fluticasone compare with equipotent doses of beclomethasone or budesonide. Lung India 2005;22(3):86-91.
48. Todevski D, Gjorcev A, Zdraveska M, Dimitrievska D, Stojkovski S, Jovkovski O. Incidence of oral candidiasis during treatment with fluticasone propionate versus beclomethasone dipropionate. European Respiratory Journal 2006;28(Suppl 50):314s.
49. Welch MJ, Nelson HS, Shapiro G, Bensch GW, Sokol WN, et al. Comparison of patient preference and ease of teaching inhaler technique for Pulmicort Turbuhaler versus pressurized metered-dose inhalers. Journal of Aerosol Medicine 2004;17(2):129-39.
50. Yiallouros PK, Milner AD, Conway E, Honour JW. Adrenal function and high dose inhaled corticosteroids for asthma. Archives of Disease in Childhood 1997;76(5):405-10.
51. Zdraveska M, Dimitrievska D, Gjorcev A, Todevski D, Dokic D. Incidence of oral candidiasis during treatment with fluticasone propionate versus beclomethasone dipropionate [Abstract]. XIX World Allergy Organization Congress; Munich, Germany. 2005:Abstract 305.
52. Zdraveska M, Gjorcev A, Dimitrievska D, Todevski D, Dokic D. Incidence of irrative pharyngeal syndrome during treatment with fluticasone propionate versus beclomethasone dipropionate [Abstract]. XIX World Allergy Organization Congress; Munich, Germany. 2005:Abstract 304.
53. Chlumsky J. Comparison of the clinical effect of fluticasone propionate and beclomethasone dipropionate in patients with bronchial asthma [Srovani klinickeho ucinku Flutikazon propionatu s Beklometazon dipropionatem u pacientu s bronchialnim astmatem]. Prakticky Lekar 1998;78(4):186-9.
54. Adams N, Bestall J, Jones PW. Budesonide for chronic asthma in children and adults (Cochrane review). Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD003274]
55. Adams N, Bestall J, Jones P. Inhaled beclomethasone at different doses for chronic asthma (Cochrane review). Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD002879]
56. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Inhaled beclomethasone versus placebo for chronic asthma (Cochrane review). Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD002738.pub2]
57. Adams N, Bestall JM, Lasserson TJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002310.pub4]
58. Adams NP, Bestall JC, Jones PW, Lasserson TJ, Griffiths B, Cates C. Inhaled fluticasone at different doses for chronic asthma (Cochrane review). Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003534.pub3]
59. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Inhaled fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4]
60. Ayres JG, Millar AB, Sykes AP. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. Respiratory Medicine 2000;94(Suppl B):S42-50.
61. British National Formulary. http://www.bnf.org.
62. Brennan VK, Osman LM, Graham H, Critchlow A, Everard ML. True device compliance: the need to consider both competence and contrivance. Respiratory Medicine 2005;99(1):97-102.
63. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ 2001;323(7318):896-900.
64. The British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax 2003;58(Suppl 1):i1-94.
65. Cates CJ. Visual Rx. Online NNT Calculator. http://www.nntonline.net/: Cates C, 2003.
66. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NIH Publication 02-3659 2002:Available at: http://www.ginasthma.com.
67. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 mug, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 mug, for the treatment of moderate asthma. Chest 1999;115(2):343-51.
68. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. European Respiratory Journal 1998;12(6):1346-53.
69. Melani AS, Zanchetta D, Barbato N, Sestini P, Cinti C, Canessa PA, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Annals of Allergy Asthma & Immunology 2004;93(5):439-46.
70. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD004109.pub2]
71. Sharek PJ, Bergman DA, Ducharme F. Beclomethasone for asthma in children: effects on linear growth. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD001282]
72. Van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone dipropionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults. Interntaional Journal of Clinical Practice 2004;58(7):678-88.
73. van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone dipropionate extrafine aerosol) in asthma (Part 2): Clinical experience in children. International Journal of Clinical Practice 2004;58(8):786-94.